Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

443

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

November 18, 2024

Study Completion Date

July 8, 2025

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

BMF-219

Investigational Product

Trial Locations (39)

10036

IMA Clinical Research Manhattan, New York

11220

Omera Health, Brooklyn

20110

Manassas Clinical Research, Manassas

27104

Wake Forest Health Network, LLC, Medical Plaza, Winston-Salem

28150

Carolina Research Center, Shelby

31015

David Kavtaradze MD, Inc, Cordele

31406

Privia Medical Group, Savannah

33010

G+C Research Group, Hialeah

33014

Panax Clinical Research, Miami Lakes

33032

Sunbright Health Research Centers, Homestead

33155

Avantis Clinical Research, Miami

33173

Century Research LLC, Miami

33176

Entrust Clinical Research, Miami

33907

Southwest General Healthcare Center, Fort Myers

37643

Medical Care, LLC, Elizabethton

44718

Diabetes and Endocrinology Associates of Stark County, Canton

60607

Cedar Crosse Research Center, Chicago

63117

IMA Clinical Research St. Louis, St Louis

75230

Velocity Clinical Research, Dallas

Zenos Clinical Research, Dallas

76710

Velocity Clinical Research, Waco

77036

Synergy Groups Medical LLC, Houston

77061

Synergy Group Medical, Houston

77459

Synergy Group Medical, Missouri City

77478

Simcare Medical Research, Sugar Land

78229

Clinical Trials of Texas, LLC, San Antonio

Diabetes & Glandular Disease Clinic, P.A., San Antonio

78745

IMA Clinical Research, Austin

84088

Velocity Clinical Research, Jordan

89119

Santa Rosa Medical Centers of Nevada, Las Vegas

90815

Ark Clinical Research, Long Beach

91303

Hope Clinical Research, Canoga Park

91763

Catalina Research Institute, LLC, Montclair

91942

Velocity Clinical Research, La Mesa

92404

Metro Clinical Trials, San Bernardino

92708

Ark Clinical Research, LLC, Fountain Valley

V5Y 3W2

BC Diabetes, Vancouver

M4G 3E8

Centricity Research LMC, Toronto

M9L 3A2

BioPharma Services Inc., Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biomea Fusion Inc.

INDUSTRY

NCT05731544 - Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) | Biotech Hunter | Biotech Hunter